Trial Search Results

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Comprehensive Cancer Network


  • Drug: Vorinostat
  • Procedure: Radiation Therapy


Phase 1


Inclusion Criteria:

   - All patients age 18 years and older with histologically proven non-small cell lung
   cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior
   surgery or radiation is allowed as long as the target metastatic lesion(s) has not
   been treated with previous radiation.

   - Adequate organ function (section 3.1.10).

   - ECOG performance status 0-2.

   - Life expectancy of >=12 weeks.

   - Systemic chemotherapy washout period >=7 days.

Exclusion Criteria:

Patients who have previously been treated with whole brain irradiation, pediatric patients
(age <18), pregnant women, and patients who are unable to give informed consent.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting